Vetecura Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 263.80%
(FY 2023)
- Profit 479.30%
(FY 2023)
- Ebitda 1444.10%
(FY 2023)
- Net Worth 487.92%
(FY 2023)
- Total Assets 214.53%
(FY 2023)
About Vetecura Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vishal Surve, Prashant Singh, and Ashwini Koli serve as directors at the Company.
- CIN/LLPIN
U24302MH2018PTC312731
- Company No.
312731
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Aug 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Ulhasnagar, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Vetecura Life Sciences Private Limited offer?
Vetecura Life Sciences Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Dog Food.
Who are the key members and board of directors at Vetecura Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashwini Koli  | Director | 01-Mar-2020 | Current |
| Vishal Surve | Director | 01-Mar-2020 | Current |
| Prashant Singh | Director | 01-Mar-2020 | Current |
Financial Performance of Vetecura Life Sciences.
Vetecura Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 263.8% increase. The company also saw a substantial improvement in profitability, with a 479.3% increase in profit. The company's net worth Soared by an impressive increase of 487.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vetecura Life Sciences?
In 2023, Vetecura Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vetecura Life Sciences?
Unlock and access historical data on people associated with Vetecura Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vetecura Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vetecura Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
